Sugi Predict

Sugi Predict / Compounds / SCHEMBL2368112

SCHEMBL2368112

SCHEMBL2368112

COC(=O)c1sc2ncnc(Cl)c2c1C

nearest known ligand 0.57

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 1/20 0.57
▸ ATM Q13315 1/20 0.54
▸ HSD17B10 Q99714 1/20 0.54
▸ MKNK2 Q9HBH9 11/20 0.49
▸ MKNK1 Q9BUB5 1/20 0.47
▸ ALDH1A1 P00352 2/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ HTT P42858 1/20 0.45
▸ KDM4E B2RXH2 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ TSHR P16473 1/20 0.44
▸ RXFP1 Q9HBX9 1/20 0.44
▸ FGFR1 P11362 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2368890 0.86 HSD17B10 (0.70) HPGDHSD17B10ALDH1A1SMN1; SMN2KDM4E
SCHEMBL2185775 0.85 HPGD (0.47) HPGDATMHSD17B10MKNK2MKNK1
SCHEMBL2185697 0.84 HSD17B10 (0.44) HPGDATMHSD17B10MKNK2MKNK1
SCHEMBL2404424 0.83 HSD17B10 (0.45) HPGDHSD17B10MKNK2MKNK1ALDH1A1
SCHEMBL2393784 0.82 MKNK2 (0.49) HSD17B10MKNK2MKNK1
SCHEMBL15787105 0.82 HSD17B10 (0.45) HPGDATMHSD17B10MKNK2ALDH1A1
SCHEMBL14965049 0.79 ALDH1A1 (0.45) HPGDHSD17B10MKNK2ALDH1A1SMN1; SMN2
SCHEMBL20504202 0.78 ALDH1A1 (0.55) HPGDATMHSD17B10ALDH1A1SMN1; SMN2
SCHEMBL3980765 0.75 MRGPRX1 (0.64) HPGDATMHSD17B10MKNK2MKNK1
SCHEMBL27705847 0.73 NOTUM (0.39) HSD17B10ALDH1A1SMN1; SMN2HTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10961216-B2 Small molecule modulators of the androgen receptor MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2021-03-30 — — US disclosed
US-10961216-B2 Small molecule modulators of the androgen receptor MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2021-03-30 — — US disclosed
US-20190202800-A1 SMALL MOLECULE MODULATORS OF THE ANDROGEN RECEPTOR NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2019-07-04 — — US disclosed
US-20190202800-A1 SMALL MOLECULE MODULATORS OF THE ANDROGEN RECEPTOR NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2019-07-04 — — US disclosed
WO-2019023651-A2 SMALL MOLECULE MODULATORS OF THE ANDROGEN RECEPTOR MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2019-01-31 — — WO disclosed
WO-2019023651-A2 SMALL MOLECULE MODULATORS OF THE ANDROGEN RECEPTOR MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2019-01-31 — — WO disclosed
EP-2331551-B1 THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS EVOTEC INTERNAT GMBH (DE) 2016-06-29 — — EP disclosed
EP-2331551-B1 THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS EVOTEC INTERNAT GMBH (DE) 2016-06-29 — — EP disclosed
EP-2539343-B1 THIENOPYRIMIDINES CONTAINING A SUBSTITUTED ALKYL GROUP FOR PHARMACEUTICAL COMPOSITIONS EVOTEC INTERNAT GMBH (DE) 2015-12-30 — — EP disclosed
EP-2539345-B1 4-[CYCLOALKYLOXY(HETERO)ARYLAMINO]-THIENO[2,3-D]PYRIMIDINES HAVING MNK1/ MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM INT (DE) 2015-07-22 — — EP disclosed
WO-2010023181-A1 THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-03-04 — — WO disclosed
US-7601725-B2 Thienopyrimidines useful as Aurora kinase inhibitors SUNESIS PHARMACEUTICALS, INC. (US) 2009-10-13 — — US disclosed
US-20080108611-A1 SUBSTITUTED THIENOPYRIMIDINE KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2008-05-08 — — US disclosed
US-20080108611-A1 SUBSTITUTED THIENOPYRIMIDINE KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2008-05-08 — — US disclosed
US-20080108611-A1 SUBSTITUTED THIENOPYRIMIDINE KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2008-05-08 — — US disclosed
WO-2007084815-A2 SUBSTITUTED THIENOPYRIMIDINE KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-07-26 — — WO disclosed
WO-2007084815-A2 SUBSTITUTED THIENOPYRIMIDINE KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-07-26 — — WO disclosed
EP-1768984-A1 THIENOPYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS Sunesis Pharmaceuticals, Inc. (US) 2007-04-04 — — EP disclosed
WO-2006036266-A1 THIENOPYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS SUNESIS PHARMACEUTICALS, INC. (US) 2006-04-06 — — WO disclosed
US-20060035908-A1 Thienopyrimidines useful as Aurora kinase inhibitors SUNESIS PHARMACEUTICALS, INC. 2006-02-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190202800-A1 SMALL MOLECULE MODULATORS OF THE ANDROGEN RECEPTOR AR, NR5A1, ESRRA HPGD 2965/4885ATM 1339/4885HSD17B10 187/4885
US-10961216-B2 Small molecule modulators of the androgen receptor AR, NR5A1, ESRRA HPGD 2965/4885ATM 1339/4885HSD17B10 187/4885
US-20080108611-A1 SUBSTITUTED THIENOPYRIMIDINE KINASE INHIBITORS MAP4K2, MAP3K6, MAP3K2 HPGD 832/4885ATM 323/4885HSD17B10 3114/4885
US-20060035908-A1 Thienopyrimidines useful as Aurora kinase inhibitors AURKA, AURKB, AURKC HPGD 3969/4885ATM 215/4885HSD17B10 3860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.